![Kevin Robert Pojasek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Kevin Robert Pojasek has worked as a Director at Ervaxx Ltd.
since 2018.
Actieve functies van Kevin Robert Pojasek
Bedrijven | Functie | Begin |
---|---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Directeur/Bestuurslid | 01-09-2018 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Health Technology |